Top

Published in:

01-03-2020 | Glucocorticoid | Review

Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review

Authors: Laura Maria Mongioì, Rosita Angela Condorelli, Federica Barbagallo, Sandro La Vignera, Aldo Eugenio Calogero

Published in: Endocrine | Issue 3/2020

Abstract

Dual-release hydrocortisone is a new hydrocortisone formulation developed to improve the pharmacokinetic and the pharmacodynamic profiles and patient compliance. The aim of this review is to summarize the main knowledge on dual-release hydrocortisone, with particular attention to pharmacokinetics, metabolic and health-related quality-of-life aspects, bone health and drug safety.

S. Bensing, A.L. Hulting, E.S. Husebye, O. Kämpe, K. Løvås, Management of endocrine disease: epidemiology, quality of life and complications of primary adrenal insufficiency: a review. Eur. J. Endocrinol. 175, R107–R116 (2016). https://doi.org/10.1530/EJE-15-1242 CrossRefPubMed

W. Arlt, B. Allolio, Adrenal insufficiency. Lancet 361, 1881–1893 (2003)CrossRef

E.S. Husebye, B. Allolio, W. Arlt, K. Badenhoop, S. Bensing, C. Betterle, A. Falorni, E.H. Gan, A.L. Hulting, A. Kasperlik-Zaluska, O. Kämpe, K. Løvås, G. Meyer, S.H. Pearce, Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014). https://doi.org/10.1111/joim CrossRefPubMed

S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016). https://doi.org/10.1210/jc.2015-1710 CrossRefPubMed

R. Bergthorsdottir, M. Leonsson-Zachrisson, A. Odén, G. Johannsson, Premature mortality in patients with Addison’s disease: a population-based study. J. Clin. Endocrinol. Metab. 91, 4849–4853 (2006)CrossRef

I.L. Ross, R. Bergthorsdottir, N.S. Levitt, D.A. Schatz, G. Johannsson, A.D. Marais, Increased cardiovascular risk in South African patients with Addison’s disease. Horm. Metab. Res. 45, 905–910 (2013). https://doi.org/10.1055/s-0033-1351259 CrossRefPubMed

I.L. Ross, R. Bergthorsdottir, N. Levitt, J.A. Dave, D. Schatz, D. Marais, G. Johannsson, Cardiovascular risk factors in patients with Addison’s disease: a comparative study of South African and Swedish patients. PLoS ONE 9, e90768 (2014). https://doi.org/10.1371/journal.pone.0090768 CrossRefPubMedPubMedCentral

H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johannsson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954–3961 (2006)CrossRef

R. Giordano, S. Marzotti, M. Balbo, S. Romagnoli, E. Marinazzo, R. Berardelli, G. Migliaretti, A. Benso, A. Falorni, E. Ghigo, E. Arvat, Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J. Endocrinological Investig. 32, 917–923 (2009). https://doi.org/10.3275/6437 CrossRef

10.

G. Johannsson, R. Bergthorsdottir, A.G. Nilsson, H. Lennernas, T. Hedner, S. Skrtic, Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur. J. Endocrinol. 161, 119–130 (2009). https://doi.org/10.1530/EJE-09-0170 CrossRefPubMed

11.

R. Giordano, F. Guaraldi, R. Berardelli, I. Karamouzis, V. D’Angelo, C. Zichi, S. Grottoli, E. Ghigo, E. Arvat, Dual-release hydrocortisone in Addison’s disease - a review of the literature. Eur. Endocrinol. 10, 75–78 (2014). https://doi.org/10.17925/EE.2014.10.01.75 CrossRefPubMedPubMedCentral

12.

G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M. Biller, J.P. Monson, P.M. Stewart, H. Lennernäs, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 (2012). https://doi.org/10.1210/jc.2011-1926 CrossRefPubMed

13.

G. Johannsson, H. Lennernäs, C. Marelli, K. Rockich, S. Skrtic, Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. Eur. J. Endocrinol. 175, 85–93 (2016). https://doi.org/10.1530/EJE-15-1212 CrossRefPubMedPubMedCentral

14.

F. Ceccato, E. Selmin, C. Sabbadin, M. Dalla Costa, G. Antonelli, M. Plebani, M. Barbot, C.Betterle, M. Boscaro, C. Scaroni, Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr. Connect. 7, 965–974 (2018). https://doi.org/10.1530/EC-18-0257

15.

M. Quinkler, R. Miodini Nilsen, K. Zopf, M. Ventz, M. Øksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015). https://doi.org/10.1530/EJE-14-1114 CrossRefPubMed

16.

R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli, I. Karamouzis, M. Lucchiari, T. Manetta, G. Mengozzi, E. Arvat, E. Ghigo, Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51, 360–368 (2016). https://doi.org/10.1007/s12020-015-0681-z CrossRefPubMed

17.

A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer, E. Sbardella, D. Gianfrilli, C. Pozza, P. Pasqualetti, S. Morrone, A. Santoni, F. Naro, A. Colao, R. Pivonello, A. Lenzi, Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173–185 (2018). https://doi.org/10.1016/S2213-8587(17)30398-4 CrossRefPubMed

18.

L.M. Mongioì, R.A. Condorelli, S. La Vignera, A.E. Calogero, Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life. Endocr. Connect. 7, 211–219 (2018). https://doi.org/10.1530/EC-17-0368 CrossRefPubMed

19.

V. Guarnotta, A. Ciresi, G. Pillitteri, C. Giordano, Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin. Endocrinol. (Oxf.). 88(5), 665–672 (2018). https://doi.org/10.1111/cen.13554 CrossRefPubMed

20.

V. Guarnotta, C. Di Stefano, A. Santoro, A. Ciresi, A. Coppola, C. Giordano, Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr. Connect. 8(7), 853–862 (2019). https://doi.org/10.1530/EC-19-0176 CrossRefPubMedPubMedCentral

21.

V. Guarnotta, M.I. Mineo, S. Radellini, G. Pizzolanti, C. Giordano, Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study. Ther. Adv. Endocrinol. Metab. 10, 2042018819871169 (2019). https://doi.org/10.1177/2042018819871169 CrossRefPubMedPubMedCentral

22.

A. Al Nofal, I. Bancos, K. Benkhadra, N.M. Ospina, A. Javed, E. Kapoor, K. Muthusamy, J.P. Brito, A.F. Turcu, Z. Wang, L. Prokop, D.Z. Erickson, A.N. Lteif, N. Natt, M.H. Murad, Glucocorticoid replacement regimens in chronic adrenal insufficiency: a systematic review and meta-analysis. Endocr. Pract. 23, 17–31 (2017). https://doi.org/10.4158/EP161428.OR CrossRefPubMed

23.

V.B. Boesen, T. Christoffersen, T. Watt, S.W. Borresen, M. Klose, U. Feldt-Rasmussen, PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open. 8(1), e019487 (2018). https://doi.org/10.1136/bmjopen-2017-019487 CrossRefPubMedPubMedCentral

24.

V. Camozzi, C. Betterle, A.C. Frigo, V. Zaccariotto, M. Zaninotto, E. De Caneva, P. Lucato, W. Gomiero, S. Garelli, C. Sabbadin, M. Salvà, M.D. Costa, M. Boscaro, G. Luisetto, Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine 59, 319–329 (2018). https://doi.org/10.1007/s12020-017-1380-8 CrossRefPubMed

25.

S. Frara, S. Chiloiro, T. Porcelli, A. Giampietro, G. Mazziotti, L. De Marinis, A. Giustina, Bone safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine 60, 528–531 (2018). https://doi.org/10.1007/s12020-017-1512-1 CrossRefPubMed

26.

D.A. Vassiliadi, S. Tsagarakis, Multiple benefits from dual release hydrocortisone: a “hard” view from bones. Endocrine 61, 177–179 (2018). https://doi.org/10.1007/s12020-018-1628-y CrossRefPubMed

27.

A.G. Nilsson, C. Marelli, D. Fitts, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, H. Lennernäs, S. Skrtic, G. Johannsson, Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. Eur. J. Endocrinol. 171, 369–377 (2014). https://doi.org/10.1530/EJE-14-0327 CrossRefPubMedPubMedCentral

28.

A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, O. Ragnarsson, S. Skrtic, J. Wahlberg, H. Achenbach, S. Uddin, C. Marelli, G. Johannsson, Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. Eur. J. Endocrinol. 176, 715–725 (2017). https://doi.org/10.1530/EJE-17-0067 CrossRefPubMedPubMedCentral

Title: Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review
Authors: Laura Maria Mongioì
Rosita Angela Condorelli
Federica Barbagallo
Sandro La Vignera
Aldo Eugenio Calogero
Publication date: 01-03-2020
Publisher: Springer US
Keyword: Glucocorticoid
Published in: Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02187-7

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Cigarette smoking is associated with higher thyroid hormone and lower TSH levels: the PREVEND study

The prevalence of heterozygous CYP21A2 deficiency in patients with idiopathic acne, hirsutism, or both

Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma

Vestibular function in severe GH deficiency due to an inactivating mutation in the GH-releasing hormone receptor gene

A novel compound heterozygous mutation of SLC12A3 gene in a Chinese pedigree with Gitelman syndrome

Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage